Pfizer, Inc. (NYSE:PFE) will issue its quarterly earnings data before the market opens on Monday, October 30th. Analysts expect the company to announce earnings of $0.64 per share for the quarter. Pfizer has set its FY17 guidance at $2.54-2.60 EPS.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 EPS. On average, analysts expect Pfizer to post $2.56 EPS for the current fiscal year and $2.76 EPS for the next fiscal year.
Shares of Pfizer, Inc. (PFE) opened at 35.60 on Friday. The stock has a 50 day moving average of $35.72 and a 200-day moving average of $33.87. The stock has a market capitalization of $211.73 billion, a P/E ratio of 26.04 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.78.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.60%. Pfizer’s dividend payout ratio is currently 94.12%.
ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) Set to Announce Quarterly Earnings on Monday” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/pfizer-inc-pfe-set-to-announce-quarterly-earnings-on-monday.html.
Several research firms have issued reports on PFE. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Jefferies Group LLC set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Monday, October 16th. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Barclays PLC set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $38.32.
In other news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the sale, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Peregrine Asset Advisers Inc. raised its stake in shares of Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC raised its stake in shares of Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 50 shares during the period. Stone House Investment Management LLC raised its stake in shares of Pfizer by 1.0% during the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 72 shares during the period. Highland Private Wealth Management raised its stake in shares of Pfizer by 0.8% during the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 76 shares during the period. Finally, Autus Asset Management LLC raised its stake in shares of Pfizer by 1.2% during the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 78 shares during the period. Institutional investors own 69.00% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.